• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

HIMS stock crashes 25% on Friday after this key FDA update

by February 22, 2025
by February 22, 2025

Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01.

The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk’s weight-loss drugs.

Despite this setback, HIMS stock had surged 43% in the past five days leading up to the FDA’s announcement, making today’s sharp drop a reversal of those recent gains.

HIMS stock was down around 21% to trade at $52.25 at the time of writing.

Novo Nordisk shortage problems resolve

The decision is expected to impact the availability of cheaper, compounded versions of Ozempic and Wegovy that telehealth companies like Hims & Hers Health have been offering.

The resolution could limit how telehealth programs provide cheaper compounded versions of weight-loss and diabetes drugs, coming two months after regulators stated there was no shortage of Eli Lilly’s treatments.

Compounded drugs—custom formulations made by mixing or altering ingredients—have surged in demand in the US due to tight supplies of blockbuster medications from Novo Nordisk and Eli Lilly.

Regulations permit compounding pharmacies to replicate brand-name drugs only when shortages exist and prohibit them from producing these drugs “regularly or in inordinate amounts.”

Companies such as Hims & Hers offer compounded semaglutide, the active ingredient in Ozempic and Wegovy.

While pharmacies may still create alternative formulations by adjusting doses or modifying ingredients, the decision is a setback for companies like Hims & Hers Health, which had benefited from offering these compounded versions.

Recent acquisitions from Hims and Hers

In separate news, the company today announced the acquisition of a US-based peptide facility in California, further verticalizing its long-term ability to deliver personalized medications.

The acquisition aims to enhance supply chain durability and meet the rising demand for personalized healthcare solutions in the US.

This move follows the company’s previous acquisitions of 503A and 503B facilities, reinforcing its domestic manufacturing capabilities and improving oversight on cost, availability, and quality.

Additionally, the peptide innovation capabilities from this acquisition will allow Hims & Hers to explore preventive health, metabolic optimization, cognitive performance, and recovery science in the coming years.

Earlier in the week, Hims & Hers Health announced the acquisition of Trybe Labs, a New Jersey-based at-home lab testing facility, further expanding its diagnostic and personalized healthcare capabilities.

The acquisition will enable Hims & Hers to offer at-home blood draws and more comprehensive pretreatment testing, providing an alternative to established blood-drawing services like Labcorp and Quest Diagnostics.

While financial terms were not disclosed, the company stated that the deal was funded through cash on hand.

The acquisition will enhance testing capabilities for LDL cholesterol, lipoprotein(a), cholesterol, and apolipoprotein.

It will also support expanded care access for conditions such as low testosterone, perimenopausal and menopausal support.

The post HIMS stock crashes 25% on Friday after this key FDA update appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why Coca-Cola says DEI is essential for business success
next post
Dow, S&P 500 slide as volatile week nears end: Celsius soars, UNH stock crashes

Related Posts

Cristiano Ronaldo joins the billionaire club, net worth...

October 8, 2025

Elon Musk’s xAI secures $20B boost as Nvidia,...

October 8, 2025

SoftBank to acquire ABB’s robotics unit for $5.4B...

October 8, 2025

European stocks open higher: CAC 40 climbs 0.11%,...

October 8, 2025

EU steel tariff surge threatens UK exports and...

October 8, 2025

Why Tata Motors stock remains in the red...

October 8, 2025

Asian markets open: Nikkei hits another record high,...

October 7, 2025

Top reasons why the Topix and Nikkei 225...

October 7, 2025

Goldman Sachs boosts 2026 gold price forecast to...

October 7, 2025

Beijing intensifies oil stockpiling amid global supply and...

October 7, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Sateliot and Nordic Enable First 5G IoT Link from LEO Satellites

    October 8, 2025
  • Have Mount Laurel Obligations Made New Jersey Housing More Affordable? A Synthetic Control Analysis of Housing Supply and Cost

    October 8, 2025
  • Rent Control Will Make the Housing Crisis Worse

    October 8, 2025
  • Gold’s Acceleration Reveals Vanishing Calm, Coming Change

    October 8, 2025
  • Why the Erosion of Central Bank Independence Matters

    October 8, 2025
  • Cristiano Ronaldo joins the billionaire club, net worth hits $1.4B

    October 8, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 5

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 6

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 7

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025

Categories

  • Economy (2,816)
  • Editor's Pick (281)
  • Investing (185)
  • Stock (1,920)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Despite drone strike, Druzhba pipeline restores oil...

August 20, 2025

Asian stocks bleed on Monday: Nikkei crashes...

March 31, 2025

Indian markets open: Sensex reclaims 80K, Nifty...

April 23, 2025